Valuation: Neuland Laboratories Limited

Market Cap 25TCr 266.31Cr 236.72Cr 219.41Cr 199.62Cr 376.7Cr 382.74Cr 2.64TCr 1.03TCr 13TCr 999.45Cr 978.17Cr 42TCr P/E 2027 *
52.9x
P/E 2028 * 40.5x
Enterprise Value 26TCr 269.14Cr 239.24Cr 221.74Cr 201.75Cr 380.71Cr 386.81Cr 2.67TCr 1.05TCr 13TCr 1.01TCr 988.58Cr 42TCr EV / Sales 2027 *
10.6x
EV / Sales 2028 * 8.75x
Free-Float
62.26%
Yield 2027 *
0.12%
Yield 2028 * 0.15%
1 day-1.22%
1 week-5.65%
Current month-7.91%
1 month-13.04%
3 months+4.93%
6 months+31.46%
Current year+29.69%
1 week 19,640
Extreme 19640
21,230
1 month 19,640
Extreme 19640
23,030.95
Current year 11,500
Extreme 11500
24,235.05
1 year 11,500
Extreme 11500
24,235.05
3 years 3,612.05
Extreme 3612.05
24,235.05
5 years 965.85
Extreme 965.85
24,235.05
10 years 247.3
Extreme 247.3
24,235.05
Manager TitleAgeSince
Chief Executive Officer 47 01/04/2026
Director of Finance/CFO - 23/11/2022
Chief Tech/Sci/R&D Officer - 01/03/2023
Director TitleAgeSince
Director/Board Member - 01/08/2025
Director/Board Member 80 31/10/2022
Director/Board Member 82 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%-5.65%+21.73%+413.47% 266.31Cr
+0.43%+6.59%+53.41%+103.85% 1,12000Cr
+0.90%-2.25%+33.02%+62.23% 62TCr
+0.71%+3.24%+25.81%+93.86% 50TCr
-0.13%+5.98%+32.91%+50.39% 37TCr
+0.52%+0.24%+73.92%+40.15% 36TCr
-0.95%+4.70%+19.51%+43.00% 29TCr
-1.98%+3.73%-0.86%+13.43% 26TCr
-0.35%+4.25%+46.21%+50.76% 23TCr
-0.75%+3.32%+32.53%+97.21% 19TCr
Average -0.28%+2.69%+33.82%+96.84% 39.44TCr
Weighted average by Cap. +0.13%+3.83%+39.17%+71.67%

Financials

2027 *2028 *
Net sales 2.42TCr 25Cr 23Cr 21Cr 19Cr 36Cr 37Cr 252.28Cr 99Cr 1.26TCr 96Cr 94Cr 4.02TCr 2.91TCr 31Cr 27Cr 25Cr 23Cr 43Cr 44Cr 303.21Cr 118.88Cr 1.52TCr 114.9Cr 112.46Cr 4.83TCr
Net income 479.83Cr 5.06Cr 4.49Cr 4.17Cr 3.79Cr 7.15Cr 7.27Cr 50Cr 20Cr 250.4Cr 19Cr 19Cr 798.23Cr 626.47Cr 6.6Cr 5.87Cr 5.44Cr 4.95Cr 9.34Cr 9.49Cr 65Cr 26Cr 326.92Cr 25Cr 24Cr 1.04TCr
Net Debt 268.96Cr 2.83Cr 2.52Cr 2.33Cr 2.12Cr 4.01Cr 4.07Cr 28Cr 11Cr 140.35Cr 11Cr 10Cr 447.42Cr 157.79Cr 1.66Cr 1.48Cr 1.37Cr 1.25Cr 2.35Cr 2.39Cr 16Cr 6.46Cr 82Cr 6.24Cr 6.11Cr 262.5Cr
Projected Income Statement - Annual - Neuland Laboratories Limited
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
16/26/16 ₹19,699.70 -1.22% 1,301
15/26/15 ₹19,942.80 -1.27% 2,966
14/26/14 ₹20,200.35 -0.74% 1,647
13/26/13 ₹20,351.90 -1.08% 3,537
12/26/12 ₹20,574.20 -1.46% 982
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Neuland Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
19,699.70INR
Average target price
24,678.50INR
Spread / Average Target
+25.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Neuland Laboratories Limited
  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock